In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 11, 2010, Pages 2411-2415

  Li, Cong Ran ^a   Li, Yi ^a   Li, Guo Qing ^a   Yang, Xin Yi ^a   Zhang, Wei Xin ^a   Lou, Ren Hui ^a   Liu, Jing Fang ^a   Yuan, Min ^a   Huang, Philip ^b   Cen, Shan ^a   Yu, Li Yan ^a   Zhao, Li Xun ^a   Jiang, Jian Dong ^a   You, Xue Fu ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b TaiGen Biopharmaceuticals Co Ltd   (China)

Author keywords

Ascending urinary tract infections; Local infections; Pulmonary infections; Systemic infections

Indexed keywords

LEVOFLOXACIN; NEMONOXACIN; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; GRAM POSITIVE INFECTION; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS CAPITIS; LEVOFLOXACIN RESISTANT STAPHYLOCOCCUS CAPITIS INFECTION; LUNG INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS CAPITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS CAPITIS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PENICILLIN INTERMEDIATE STREPTOCOCCUS PNEUMONIAE; PENICILLIN INTERMEDIATE STREPTOCOCCUS PNEUMONIAE INFECTION; PENICILLIN RESISTANT STREPTOCOCCUS PNEUMONIAE; PENICILLIN RESISTANT STREPTOCOCCUS PNEUMONIAE INFECTION; PERITONITIS; PNEUMOCOCCAL INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; MALE; MICE; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; QUINOLONES; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 77957863841     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq341     Document Type: Article

References (16)

1. Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother 2003; 51 Suppl 1: 1-11.
2. Peterson LR. Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clin Infect Dis 2001; 33 Suppl 3: S180-6.
3. Barry AL, Fuchs PC, Brown SD. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates. Antimicrob Agents Chemother 2001; 45: 1923-7.
4. Adam HJ, Laing NM, King CR et al. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother 2009; 53: 4915-20.
5. Chen YH, Liu CY, Lu JJ et al. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J Antimicrob Chemother 2009; 64: 1226-9.
6. O'Reilly T, Andes DA, Østergaard C et al. Evaluation of antimicrobials in experimental animal infections. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Philadelphia, PA: Lippincott Williams & Wilkins, 2005; 654-718.
7. Litchfield JT Jr, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949; 96: 99-113.
8. Tateda K, Takashima K, Miyazaki H et al. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob Agents Chemother 1996; 40: 1520-5.
9. Hoshino K, Inoue K, Murakami Y et al. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob Agents Chemother 2008; 52: 65-76.
10. Moine P, Vallee E, Azoulay-Dupuis E et al. In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother 1994; 38: 1953-8.
11. Azoulay-Dupuis E, Vallee E, Veber B et al. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob Agents Chemother 1992; 36: 2698-703.
12. Tsuji M, Takema M, Miwa H et al. In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models. Antimicrob Agents Chemother 2003; 47: 2507-12.
13. Hvidberg H, Struve C, Krogfelt KA et al. Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies. Antimicrob Agents Chemother 2000; 44: 156-63.
14. Hsu CH, Lin L, Leunk R et al. In vivo efficacy of nemonoxacin in a mouse pulmonary infection model. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy and Forty-sixth Infectious Diseases Society of America Joint Meeting, Washington, DC, 2008. Abstract B-056, p. 4. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC, USA.
15. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
16. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. CLSI, Wayne, PA, USA, 2010.